Ironwood Pharmaceuticals (IRWD) News Today

$6.48
-0.16 (-2.41%)
(As of 05/17/2024 08:53 PM ET)
BNP Paribas Financial Markets Has $6.56 Million Stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
BNP Paribas Financial Markets increased its position in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 35.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 572,947 shares of the biotechnology com
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 2.4%
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 2.4%
Ironwood Pharmaceuticals Inc Class A
Ironwood Pharmaceuticals (NASDAQ:IRWD) Releases Quarterly Earnings Results, Misses Expectations By $0.20 EPS
Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.20). The company had revenue of $74.90 million during the quarter, compared to the consensus estimate of $105.75 million. Ironwood Pharmaceuticals had a negative net margin of 226.37% and a negative return on equity of 185.45%. The firm's revenue was down 28.0% on a year-over-year basis. During the same period in the previous year, the business posted $0.25 earnings per share.
Craig Hallum Cuts Ironwood Pharmaceuticals (NASDAQ:IRWD) Price Target to $14.00
Craig Hallum reduced their target price on shares of Ironwood Pharmaceuticals from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Friday.
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down to $8.12
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down to $8.12
Victory Capital Management Inc. Lowers Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Victory Capital Management Inc. lowered its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 4.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,224,583 shares of
LSV Asset Management Lowers Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
LSV Asset Management lessened its holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 5.3% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 6,782,101 shares of the biotechnology company's stock after selling 382,108 sha
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Expected to Earn FY2025 Earnings of $0.88 Per Share
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Research analysts at Capital One Financial boosted their FY2025 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a research report issued on Wednesday, May 1st. Capital One Financial analyst T. Chiang now for
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 5.5% Higher
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Up 5.5%
5 Best Low Price Pharma Stocks To Invest In
Guru Fundamental Report for IRWD
Ironwood Pharmaceuticals (NASDAQ:IRWD) Reaches New 52-Week Low at $7.78
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sets New 1-Year Low at $7.78
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Update
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) was the target of a large growth in short interest in March. As of March 31st, there was short interest totalling 21,950,000 shares, a growth of 16.9% from the March 15th total of 18,770,000 shares. Approximately 14.5% of the shares of the stock are sold short. Based on an average daily trading volume, of 4,770,000 shares, the days-to-cover ratio is presently 4.6 days.
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 2.9%
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Down 2.9%
Ironwood Pharmaceuticals (NASDAQ:IRWD) Sets New 52-Week Low at $8.07
Ironwood Pharmaceuticals (NASDAQ:IRWD) Hits New 12-Month Low at $8.07
Piper Sandler Reaffirms Their Buy Rating on Ironwood Pharma (IRWD)
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Rating of "Buy" from Analysts
Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have received a consensus rating of "Buy" from the five brokerages that are currently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation. The average 1 year price ta
Ironwood Pharmaceuticals (NASDAQ:IRWD) Upgraded to "Buy" by StockNews.com
StockNews.com raised shares of Ironwood Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday.
Equities Analysts Set Expectations for Ironwood Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Equities research analysts at Zacks Research lifted their FY2024 earnings per share estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, March 20th. Zacks Research analyst R. Department now forecasts that the b
Research Analysts Offer Predictions for Ironwood Pharmaceuticals, Inc.'s Q4 2024 Earnings (NASDAQ:IRWD)
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Investment analysts at Zacks Research lifted their Q4 2024 earnings estimates for shares of Ironwood Pharmaceuticals in a research report issued on Wednesday, March 20th. Zacks Research analyst R. Department now forecasts that the biote
Walleye Capital LLC Purchases Shares of 166,968 Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Walleye Capital LLC purchased a new stake in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) during the third quarter, according to its most recent filing with the SEC. The fund purchased 166,968 shares of the biotechnology company's stock, valued at approximately $1,608,000. Walleye Cap
2,378,295 Shares in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Purchased by Jacobs Levy Equity Management Inc.
Jacobs Levy Equity Management Inc. bought a new position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) during the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,378,295 shares of the biotechnology company's st
Q1 2025 EPS Estimates for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Cut by Zacks Research
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a research note issued to investors on Thursday, March 7th. Zacks Research analyst R. Department now expects t
Adage Capital Partners GP L.L.C. Boosts Stock Holdings in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
Adage Capital Partners GP L.L.C. lifted its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) by 160.9% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,462,300 shares of the biotechnolo
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Recommendation of "Buy" by Analysts
Shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Get Free Report) have been given a consensus rating of "Buy" by the five brokerages that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 1-year target pri
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) to Post Q1 2024 Earnings of $0.18 Per Share, Zacks Research Forecasts
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Investment analysts at Zacks Research lifted their Q1 2024 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a note issued to investors on Monday, March 4th. Zacks Research analyst R. Department now expects th
Get Ironwood Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.

He called Apple at $1.49 and now he says: “Buy these 6 AI stocks.” (Ad)

For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market.

Click for his six specific AI stock in the crosshairs

IRWD Media Mentions By Week

IRWD Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IRWD
News Sentiment

0.10

0.42

Average
Medical
News Sentiment

IRWD News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IRWD Articles
This Week

8

3

IRWD Articles
Average Week

Get Ironwood Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

This page (NASDAQ:IRWD) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners